This suggests that the anti-CD96 and anti-PD-1 antibodies induced considerably different amounts of ADAs, indicating that the mAbs triggered very different extents of immunogenicity in the mouse colon cancer model. This evidence concerns the gene AGPS and colonic neoplasm.